EC Number   |
Activating Compound |
Reference |
|---|
    2.7.1.91 | (2S)-2-(3-[6-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)methoxy]naphthalen-2-yl]-1,2,4-oxadiazol-5-yl)pyrrolidine-1-carboximidamide |
isoform SphK2 shows 104% activity at 0.001 mM |
760267 |
| 2.7.1.91 | (2S)-2-[3-(6-hydroxynaphthalen-2-yl)-1,2,4-oxadiazol-5-yl]pyrrolidine-1-carboximidamide |
isoform SphK2 shows 106% activity at 0.001 mM |
760267 |
| 2.7.1.91 | (2S)-2-[3-[6-(2-methoxyethoxy)naphthalen-2-yl]-1,2,4-oxadiazol-5-yl]pyrrolidine-1-carboximidamide |
isoform SphK2 shows 118% activity at 0.001 mM |
760267 |
| 2.7.1.91 | (2S)-2-[3-[6-(2-oxo-2-phenylethoxy)naphthalen-2-yl]-1,2,4-oxadiazol-5-yl]pyrrolidine-1-carboximidamide |
isoform SphK2 shows 103% activity at 0.001 mM |
760267 |
| 2.7.1.91 | (2S)-2-[3-[6-(3-methoxypropoxy)naphthalen-2-yl]-1,2,4-oxadiazol-5-yl]pyrrolidine-1-carboximidamide |
isoform SphK2 shows 109% activity at 0.001 mM |
760267 |
| 2.7.1.91 | (4-hydroxypiperidin-1-yl)(4-octylphenyl)methanone |
- |
738830 |
| 2.7.1.91 | 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid |
treatment markedly augments SK activity in HUVECs. At the concentration of 1 mM, 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid increases SK activity by 110% and the maximal effect on SK activation is observed at 20 min after 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid addition. Inhibition of SK by a specific inhibitor, SKI-II, markedly attenuates 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid-induced endothelial cell proliferation. 11,12-Epoxy-(5Z,8Z,14Z)-eicosatrienoic acid-induced activation of Akt kinase and transactivation of the epidermal growth factor receptor are also inhibited by SKI-II |
703085 |
| 2.7.1.91 | 12-O-tetradecanoylphorbol-13-acetate |
50 nM, maximum increase in activity after 24 h |
672377 |
| 2.7.1.91 | 2-[4-(4-octyl-1H-1,2,3-triazol-1-yl)phenyl]ethanol |
- |
738830 |
| 2.7.1.91 | 4-(4-octyl-1H-1,2,3-triazol-1-yl)phenol |
- |
738830 |
